Navigation Links
Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Date:11/4/2010

SAN DIEGO, Nov. 4, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010. APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, which, along with other compounds and intellectual property, will revert to Arena upon termination of the collaboration. Arena owns a patent portfolio covering a broad array of internally discovered, oral GPR119 agonists, including next generation compounds that were not part of the collaboration.

The Phase 1 program evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597, and included single and multi-ascending studies in healthy volunteers and in subjects with type 2 diabetes. APD597 was well tolerated and showed dose-proportional pharmacokinetics with a half-life of six to seven hours in solution and approximately 13 hours in suspension in healthy volunteers. The Phase 1 program also provided evidence for incretin stimulation (GLP-1, GIP and PYY) and reductions in post-meal glucose increases with APD597 treatment in both overweight and obese non-diabetic volunteers and in subjects with type 2 diabetes. In general, reductions in post-meal glucose increases were greater with APD597 in combination with sitagliptin, a DPP-4 inhibitor, compared to sitagliptin alone.

"Results of the Phase 1 program suggest that APD597 may have utility both alone and in combination with a DPP-4 inhibitor for the treatment of type 2 diabetes," said Jack Lief, Arena's President and Chief Executive Officer. "With our existing GPR119 patent portfolio, internally discovered next generation compounds a
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
2. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
3. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
4. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
6. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
9. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... Lightlake,s partner for treating opioid overdose with intranasal ... New Drug Application (NDA) to the United States ... spray formulation of naloxone, a drug intended to ...
(Date:6/3/2015)... 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... license agreement with AbbVie (NYSE: ABBV ) to ... with Halozyme,s ENHANZE ™ platform. ... will receive an initial $23 million payment, followed ... each of up to nine collaboration targets. These ...
(Date:6/3/2015)... 2015  VA North Texas Health Care System ... vBloc, a technology-based, scientifically advanced weight loss therapy.  ... called the Maestro® Rechargeable System that intermittently blocks ... involving food intake and processing between the brain ... customizable to meet the needs of a patient,s ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 2VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 3
(Date:6/3/2015)... EMBARGOED FOR RELEASE UNTIL 2 P.M. ET, WEDNESDAY, ... of Mother’s Home to Gas Wells , PITTSBURGH, June 3, ... of natural gas wells drilled with hydraulic fracturing were more ... living farther from such wells, according to a University ... southwestern Pennsylvania birth records. , The finding does not ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 ... agreed to pay $7.8 million to resolve a Risperdal ... Arkansas over tactics the company allegedly used to market ... County Circuit Court indicate that the Arkansas Attorney General ... part of the accord. The Risperdal settlement amounts to ...
(Date:6/3/2015)... 2015 Follow us on LinkedIn ... revolutionized disease treatment on account of their better mode ... such as rheumatoid arthritis. The industry is expected to ... small molecule drugs to biopharmaceuticals over the coming years. ... and gene therapies, and recombinant proteins has attracted industry ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Dr. Steven Reisman, ... Cardiac Diagnostic Center ( http://www.newyorkcardiac.com ) located in NYC, announced ... weekdays to his practice. In most cases, depending on the ... the day they call, they will be seen by a ... priority as a cardiologist is to ensure that people who ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 ... strategic partnership to expand online and mobile access ... Board Review and Maintenance of Certification (MOC) activities. ... will market VeoMed’s innovative courses to Decker’s extensive ... professionals interested in purchasing access to VeoMed’s premier ...
Breaking Medicine News(10 mins):Health News:Fracking Proximity Associated with Lower Birth Weight 2Health News:Fracking Proximity Associated with Lower Birth Weight 3Health News:Fracking Proximity Associated with Lower Birth Weight 4Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2
... The Sanitizer, Game Allows Consumers to Zap Germs in the Water Just ... ... 20 Just in time for Memorial Day,integrated marketing communications agency, Fletcher ... BioGuard,s new UV sanitizing unit, BioLab UV ( http://www.biolabuv.com ). ...
... is a well known disease entity that has a wide ... the colonic blood supply is key to its development. However, ... causes ischemia of the bowel. This report describes the first ... and splenic veins. , This case report, from a ...
... not uncommon to find tissue that normally lines the stomach ... tissue has been identified in such diverse locations as the ... case, reported by a team led by Dr. Steven Paul ... the World Journal of Gastroenterology. , Typically, when this gastric ...
... no obvious effects on MKN-45 cells proliferation and apoptosis. At ... apoptosis improved. It may be that CO2 gas affected the ... by a team led by Professor Pei-Wu Yu. The research ... World Journal of Gastroenterology. , There is an ongoing debate ...
... and calm, according to a new study from the Population ... at about age 60, participants reported more feelings of ease ... John Mirowsky, professors of sociology, have published the findings in ... issue of Social Science and Medicine. The research was funded ...
... substantial financial income and the ... chance to change people,s lives, ... so,people are increasingly looking for new ways to make the ... Today, that,s,possible with the independent marketing opportunities provided by,Melaleuca, The ...
Cached Medicine News:Health News:Fletcher Martin Creates Interactive Game-Ad for BioLab(R) UV for BioGuard(R) 2Health News:Heterotopic gastric tissue simulating acute appendicitis 2Health News:With age comes a sense of peace and calm 2Health News:Lucrative Sales Opportunities Abound With Melaleuca, The Wellness Company(R) 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: